思创 公司是一家以色谱技术为核心，集研发、生产和销售于一体的高新技术企业，主要为制药、生命科学等 领域提供专业的分离纯化装备、耗材、应用技术服务及相关的技术解决方案。 注：本文系新闻报道，不构成投资建议，股市有风险，投资需谨慎。 从资金流向来看，上市首日该股获主力资金净流入2.10亿元，其中，特大单净流入8152.21万元，大单净 流入1.29亿元。（数据宝） （文章来源：证券时报网） 近期上市新股首日融资融券交易明细 C汉邦（688755）上市首日上涨102.46%，换手率达75.65%，成交额为6.09亿元。 | 代码 | 简称 | 上市日期 | 上市首日涨跌 | 上市首日融资余额 | 占流通市值比 | 上市首日融券余额 | | --- | --- | --- | --- | --- | --- | --- | | | | | （%） | （万元） | 例（%） | （万元） | | 688755 | C汉邦 | 2025.05.16 | 102.46 | 4176.33 | 5.48 | 0.00 | | 301636 | C泽润 | 2025.05.16 | 99.52 | 2306.48 | 2.3 ...

N汉邦今日上市，开盘价49.00元，上涨115.20%。 公司是一家以色谱技术为核心，集研发、生产和销售于一体的高新技术企业，主要为制药、生命科学等 领域提供专业的分离纯化装备、耗材、应用技术服务及相关的技术解决方案。 证券时报·数据宝统计显示，公司本次发行总量为2200.00万股，其中，网上发行量为704.00万股，发行 价格为22.77元/股，发行市盈率26.35倍，行业平均市盈率28.04倍，网上发行有效申购户数为505.71万 户，网上发行最终中签率为0.03001029%。公司首发募集资金5.01亿元，募集资金主要投向补充流动资 金、色谱分离装备研发中心建设项目、年产2000台(套)实验室色谱分离纯化仪器生产项目、年产1000台 液相色谱系列分离装备生产项目等。（数据宝） 近期上市新股首日表现 | 代码 | 简称 | 上市日期 | 发行价（元） | 发行市盈率（倍） | 首日开盘涨跌幅（%） | 所属行业 | | --- | --- | --- | --- | --- | --- | --- | | 688755 | N汉邦 | 2025.05.16 | 22.77 | 26.35 | 115.20 ...

Company Overview - Hanbang Technology is a high-tech enterprise focused on chromatography technology, providing professional separation and purification equipment, consumables, application technology services, and related technical solutions primarily for the pharmaceutical and life sciences sectors [1]. IPO Details - The company is set to launch its public offering with a total share capital of 66 million shares, of which 22 million shares will be publicly issued, representing 25% of the post-issue total share capital [1]. - The issue price is set at 22.77 yuan per share, with an earnings per share (EPS) ratio of 26.35 times, compared to the industry average of 28.04 times [1]. - The maximum subscription limit for a single account is 5,000 shares, requiring a minimum market value of 50,000 yuan in the Shanghai market for top-tier subscriptions [1]. Fundraising Allocation - The funds raised will be allocated to several projects, including: - Production project for 1,000 units of liquid chromatography series separation equipment (193.03 million yuan) - Construction of a chromatography separation equipment R&D center (271.10 million yuan) - Production project for 2,000 units of laboratory chromatography separation and purification instruments (224.76 million yuan) - Supplementing working capital (291.11 million yuan) [1]. Financial Performance - Key financial indicators for Hanbang Technology include: - Total assets for 2024 are projected at 1.32 billion yuan, a decrease from 1.35 billion yuan in 2023 and 1.40 billion yuan in 2022 [1]. - Net assets have increased to 739.63 million yuan in 2024 from 638.37 million yuan in 2023 and 566.92 million yuan in 2022 [1]. - Operating revenue is expected to reach 690.88 million yuan in 2024, up from 619.01 million yuan in 2023 and 481.79 million yuan in 2022 [1]. - Net profit attributable to shareholders is projected at 79.34 million yuan for 2024, compared to 51.50 million yuan in 2023 and 38.56 million yuan in 2022 [1]. - Basic and diluted earnings per share are both expected to be 1.20 yuan in 2024, up from 0.78 yuan in 2023 and 0.62 yuan in 2022 [1]. - The weighted average return on equity is projected at 11.51% for 2024, an increase from 8.55% in 2023 and 9.86% in 2022 [1]. - Net cash flow from operating activities is expected to be 129.88 million yuan in 2024, compared to 113.33 million yuan in 2023 and 19.84 million yuan in 2022 [1]. - R&D investment is projected at 41.85 million yuan in 2024, representing 6.06% of operating revenue, consistent with previous years [1].